Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
Authors:
Sharon L. Mulvagh1; Silvio E. Inzucchi2; Nikolaus Marx3; Neil Poulter4; John E. Deanfield5; Rodica Pop-Busui6; Scott Emerson7; Johannes F. E. Mann8; Mads D. Engelmann9; G. Kees Hovingh9; Kabirdev Mandavya10; Zaklina Davicevic-Elez9; Ole Kleist Jeppesen9; Alberto Lorenzatti11; Aytekin Oguz12; Boris Mankovsky13; Chaicharn Deerochanawong14; Juan Jose Gorgojo Martinez15; Linong Ji16; Stephen C. Bain17; Darren K. McGuire18; John B. Buse19; on behalf of the SOUL Study Group
Affiliations
View DetailsHide Details
{{ getPageNum(PDFPage) }}
Share
Copy link
{{pageUrl}}
Keywords
Diabetes
Congress oral presentation
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)
Get notified when materials for ESC 2025 and future congresses become available:
Slide decks
Posters
Videos ... and more.
Get notified when materials for ESC 2025 and future congresses become available:
Slide decks
Posters
Videos ... and more.
{{ error.$message }}
Success
We will notify you when new materials become available for ESC 2025 and future congresses.
We will keep you updated in your inbox:
Subscribe to receive updates on related congresses in the same disease area: